R
Ronald M. Witteles
Researcher at Stanford University
Publications - 156
Citations - 9815
Ronald M. Witteles is an academic researcher from Stanford University. The author has contributed to research in topics: Amyloidosis & Medicine. The author has an hindex of 34, co-authored 131 publications receiving 7244 citations. Previous affiliations of Ronald M. Witteles include French Institute of Health and Medical Research & University of Chicago.
Papers
More filters
Journal ArticleDOI
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial
Murray D. Esler,Henry Krum,Paul A. Sobotka,Markus P. Schlaich,Roland E. Schmieder,Michael Böhm,Felix Mahfoud,Horst Sievert,Nina Wunderlich,Lars Christian Rump,Oliver Vonend,Michael Uder,Mel Lobo,Mark J. Caulfield,Andrejs Erglis,Michel Azizi,Marc Sapoval,S. Thambar,Alexandre Persu,Jean Renkin,Heribert Schunkert,Joachim Weil,Uta C. Hoppe,Tony Walton,Dierk Scheinert,Thomas Binder,Andrzej Januszewicz,Adam Witkowski,Luis M. Ruilope,Robert Whitbourn,Heike Bruck,Mark Downes,Thomas F. Lüscher,Alan G. Jardine,Mark Webster,Thomas Zeller,Jerzy Sadowski,Krzysztof Bartus,Craig A. Straley,Neil C. Barman,David P. Lee,Ronald M. Witteles,Vivek Bhalla,Joseph M. Massaro +43 more
TL;DR: Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients and should be continued, according to the authors.
Journal ArticleDOI
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer,Jeffrey H. Schwartz,Balarama Gundapaneni,Perry M. Elliott,Giampaolo Merlini,Márcia Waddington-Cruz,Arnt V. Kristen,Martha Grogan,Ronald M. Witteles,Thibaud Damy,Brian M. Drachman,Sanjiv J. Shah,Mazen Hanna,Daniel P. Judge,Alexandra I. Barsdorf,Peter Huber,Terrell A. Patterson,Steven Riley,Jennifer Schumacher,Michelle Stewart,Marla B. Sultan,Claudio Rapezzi +21 more
TL;DR: In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all‐cause mortality and cardiovascular‐related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo.
Journal ArticleDOI
Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
Paul W. Burridge,Yong Fuga Li,Elena Matsa,Haodi Wu,Sang-Ging Ong,Arun Sharma,Alexandra Holmström,Alex C.Y. Chang,Michael Coronado,Antje D. Ebert,Joshua W. Knowles,Melinda L. Telli,Ronald M. Witteles,Helen M. Blau,Daniel Bernstein,Russ B. Altman,Joseph C. Wu +16 more
TL;DR: It is demonstrated that patient-specific human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) can recapitulate the predilection to doxorubicin-induced cardiotoxicity of individual patients at the cellular level.
Journal ArticleDOI
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Giuseppe Curigliano,Daniel J. Lenihan,Michael G. Fradley,Sarju Ganatra,Ana Barac,Anne H. Blaes,Jörg Herrmann,Charles B. Porter,Alexander R. Lyon,Patrizio Lancellotti,Aarti Patel,Jeanne M. DeCara,Joshua D. Mitchell,Eric E. Harrison,Javid Moslehi,Ronald M. Witteles,Maria Grazia Calabrò,Roberto Orecchia,E. de Azambuja,J. L. Zamorano,Ron Krone,Zaza Iakobishvili,Joseph R. Carver,Saro H. Armenian,Bonnie Ky,Daniela Cardinale,Carlo M. Cipolla,Susan Dent,Karin Jordan +28 more
TL;DR: Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment, and guidance regarding prevention, screening, monitoring and treatment of CV toxicity is provided.
Journal ArticleDOI
Insulin-Resistant Cardiomyopathy : Clinical Evidence, Mechanisms, and Treatment Options
TL;DR: Clinical studies in humans and animal models strongly support the link between insulin resistance and nonischemic HF, and potential options for treatment include metabolic-modulating agents and antidiabetic drugs.